Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsG1 Therapeutics, Inc. announced that it is supporting a Phase II investigator-initiated study of trilaciclib and lurbinectedin in patients with extensive stage NSCLC.
[G1 Therapeutics, Inc.]
Home Newsletters G1 Therapeutics Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin in Patients...
